nodes	percent_of_prediction	percent_of_DWPC	metapath
Iloperidone—CYP1A2—Anagrelide—hematologic cancer	0.0281	0.0464	CbGbCtD
Iloperidone—CYP2E1—Thalidomide—hematologic cancer	0.018	0.0297	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.0164	0.0271	CbGbCtD
Iloperidone—CYP3A7—Ifosfamide—hematologic cancer	0.0164	0.0271	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.0157	0.0259	CbGbCtD
Iloperidone—CYP3A7—Imatinib—hematologic cancer	0.0157	0.0259	CbGbCtD
Iloperidone—CYP2E1—Dacarbazine—hematologic cancer	0.0155	0.0255	CbGbCtD
Iloperidone—CYP3A5—Daunorubicin—hematologic cancer	0.0154	0.0253	CbGbCtD
Iloperidone—CYP2D6—Lomustine—hematologic cancer	0.0149	0.0246	CbGbCtD
Iloperidone—CYP1A2—Carmustine—hematologic cancer	0.0148	0.0244	CbGbCtD
Iloperidone—CYP3A5—Thalidomide—hematologic cancer	0.014	0.0231	CbGbCtD
Iloperidone—CYP3A5—Teniposide—hematologic cancer	0.0133	0.022	CbGbCtD
Iloperidone—CYP2D6—Idarubicin—hematologic cancer	0.0133	0.022	CbGbCtD
Iloperidone—CYP1A2—Methoxsalen—hematologic cancer	0.0126	0.0207	CbGbCtD
Iloperidone—CYP3A5—Ifosfamide—hematologic cancer	0.0123	0.0203	CbGbCtD
Iloperidone—CYP2E1—Mitoxantrone—hematologic cancer	0.012	0.0198	CbGbCtD
Iloperidone—CYP1A2—Bortezomib—hematologic cancer	0.0119	0.0197	CbGbCtD
Iloperidone—CYP3A5—Imatinib—hematologic cancer	0.0118	0.0194	CbGbCtD
Iloperidone—CYP1A2—Daunorubicin—hematologic cancer	0.0114	0.0189	CbGbCtD
Iloperidone—CYP2D6—Hydroxyurea—hematologic cancer	0.0113	0.0187	CbGbCtD
Iloperidone—CYP1A2—Alitretinoin—hematologic cancer	0.0112	0.0185	CbGbCtD
Iloperidone—CYP1A2—Thalidomide—hematologic cancer	0.0104	0.0172	CbGbCtD
Iloperidone—CYP3A4—Bexarotene—hematologic cancer	0.0102	0.0169	CbGbCtD
Iloperidone—CYP2D6—Bortezomib—hematologic cancer	0.00985	0.0163	CbGbCtD
Iloperidone—CYP3A7—Irinotecan—hematologic cancer	0.00979	0.0162	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.00979	0.0162	CbGbCtD
Iloperidone—CYP3A4—Busulfan—hematologic cancer	0.0095	0.0157	CbGbCtD
Iloperidone—CYP3A4—Lomustine—hematologic cancer	0.0095	0.0157	CbGbCtD
Iloperidone—CYP3A5—Dasatinib—hematologic cancer	0.00945	0.0156	CbGbCtD
Iloperidone—CYP1A2—Dacarbazine—hematologic cancer	0.00895	0.0148	CbGbCtD
Iloperidone—CYP1A2—Imatinib—hematologic cancer	0.00875	0.0145	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.00856	0.0141	CbGbCtD
Iloperidone—CYP3A7—Vincristine—hematologic cancer	0.00856	0.0141	CbGbCtD
Iloperidone—CYP3A4—Thiotepa—hematologic cancer	0.00846	0.014	CbGbCtD
Iloperidone—CYP2E1—Etoposide—hematologic cancer	0.00757	0.0125	CbGbCtD
Iloperidone—CYP3A5—Irinotecan—hematologic cancer	0.00735	0.0121	CbGbCtD
Iloperidone—CYP2D6—Imatinib—hematologic cancer	0.00721	0.0119	CbGbCtD
Iloperidone—CYP1A2—Dasatinib—hematologic cancer	0.00703	0.0116	CbGbCtD
Iloperidone—CYP3A4—Methoxsalen—hematologic cancer	0.00658	0.0109	CbGbCtD
Iloperidone—CYP2D6—Nilotinib—hematologic cancer	0.00655	0.0108	CbGbCtD
Iloperidone—CYP2D6—Vinorelbine—hematologic cancer	0.0065	0.0107	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.00645	0.0106	CbGbCtD
Iloperidone—CYP3A7—Dexamethasone—hematologic cancer	0.00645	0.0106	CbGbCtD
Iloperidone—CYP3A5—Vincristine—hematologic cancer	0.00642	0.0106	CbGbCtD
Iloperidone—CYP3A4—Bortezomib—hematologic cancer	0.00626	0.0103	CbGbCtD
Iloperidone—CYP2E1—Dexamethasone—hematologic cancer	0.00623	0.0103	CbGbCtD
Iloperidone—CYP3A4—Daunorubicin—hematologic cancer	0.00599	0.00988	CbGbCtD
Iloperidone—CYP3A5—Etoposide—hematologic cancer	0.00588	0.00971	CbGbCtD
Iloperidone—CYP3A4—Cytarabine—hematologic cancer	0.00528	0.00872	CbGbCtD
Iloperidone—CYP3A4—Teniposide—hematologic cancer	0.0052	0.00859	CbGbCtD
Iloperidone—CYP3A5—Dexamethasone—hematologic cancer	0.00484	0.00799	CbGbCtD
Iloperidone—CYP3A4—Ifosfamide—hematologic cancer	0.0048	0.00793	CbGbCtD
Iloperidone—CYP3A4—Imatinib—hematologic cancer	0.00459	0.00757	CbGbCtD
Iloperidone—CYP1A2—Etoposide—hematologic cancer	0.00438	0.00723	CbGbCtD
Iloperidone—CYP3A4—Ruxolitinib—hematologic cancer	0.00432	0.00713	CbGbCtD
Iloperidone—CYP3A4—Nilotinib—hematologic cancer	0.00417	0.00688	CbGbCtD
Iloperidone—CYP3A4—Vinorelbine—hematologic cancer	0.00413	0.00682	CbGbCtD
Iloperidone—CYP2D6—Vinblastine—hematologic cancer	0.00401	0.00661	CbGbCtD
Iloperidone—CYP3A4—Triamcinolone—hematologic cancer	0.00378	0.00624	CbGbCtD
Iloperidone—CYP3A4—Dasatinib—hematologic cancer	0.00368	0.00608	CbGbCtD
Iloperidone—CYP3A4—Mitoxantrone—hematologic cancer	0.00364	0.00601	CbGbCtD
Iloperidone—CYP3A4—Betamethasone—hematologic cancer	0.00324	0.00535	CbGbCtD
Iloperidone—CYP3A4—Prednisolone—hematologic cancer	0.0032	0.00528	CbGbCtD
Iloperidone—CYP3A4—Prednisone—hematologic cancer	0.00302	0.00499	CbGbCtD
Iloperidone—CYP2D6—Dexamethasone—hematologic cancer	0.00297	0.0049	CbGbCtD
Iloperidone—CYP3A4—Irinotecan—hematologic cancer	0.00286	0.00473	CbGbCtD
Iloperidone—CYP3A4—Vinblastine—hematologic cancer	0.00255	0.0042	CbGbCtD
Iloperidone—CYP3A4—Vincristine—hematologic cancer	0.0025	0.00413	CbGbCtD
Iloperidone—CYP2D6—Doxorubicin—hematologic cancer	0.00246	0.00406	CbGbCtD
Iloperidone—Risperidone—H1F0—hematologic cancer	0.00234	0.707	CrCbGaD
Iloperidone—CYP3A4—Etoposide—hematologic cancer	0.00229	0.00379	CbGbCtD
Iloperidone—CYP3A4—Dexamethasone—hematologic cancer	0.00189	0.00311	CbGbCtD
Iloperidone—CYP3A4—Doxorubicin—hematologic cancer	0.00157	0.00258	CbGbCtD
Iloperidone—DRD4—testis—hematologic cancer	0.0011	0.0599	CbGeAlD
Iloperidone—HTR1A—hematopoietic system—hematologic cancer	0.000661	0.036	CbGeAlD
Iloperidone—HTR7—hematopoietic system—hematologic cancer	0.000632	0.0344	CbGeAlD
Iloperidone—ADRA1A—hematopoietic system—hematologic cancer	0.00061	0.0332	CbGeAlD
Iloperidone—CYP1A2—hematopoietic system—hematologic cancer	0.000504	0.0274	CbGeAlD
Iloperidone—SIGMAR1—blood—hematologic cancer	0.00049	0.0267	CbGeAlD
Iloperidone—CYP3A5—hematopoietic system—hematologic cancer	0.000486	0.0265	CbGeAlD
Iloperidone—HTR7—gonad—hematologic cancer	0.000481	0.0262	CbGeAlD
Iloperidone—SIGMAR1—bone marrow—hematologic cancer	0.000474	0.0258	CbGeAlD
Iloperidone—HRH1—hematopoietic system—hematologic cancer	0.000472	0.0257	CbGeAlD
Iloperidone—ADRA2A—hematopoietic system—hematologic cancer	0.000464	0.0252	CbGeAlD
Iloperidone—CYP2E1—hematopoietic system—hematologic cancer	0.000454	0.0247	CbGeAlD
Iloperidone—SIGMAR1—lung—hematologic cancer	0.00043	0.0234	CbGeAlD
Iloperidone—HTR7—blood—hematologic cancer	0.000419	0.0228	CbGeAlD
Iloperidone—SIGMAR1—testis—hematologic cancer	0.000405	0.0221	CbGeAlD
Iloperidone—ADRA1A—blood—hematologic cancer	0.000404	0.022	CbGeAlD
Iloperidone—HTR2A—hematopoietic system—hematologic cancer	0.000394	0.0215	CbGeAlD
Iloperidone—Gefitinib—ABCG2—hematologic cancer	0.000393	0.119	CrCbGaD
Iloperidone—ADRA2C—blood—hematologic cancer	0.000385	0.021	CbGeAlD
Iloperidone—HTR7—lung—hematologic cancer	0.000367	0.02	CbGeAlD
Iloperidone—CYP3A4—hematopoietic system—hematologic cancer	0.000365	0.0199	CbGeAlD
Iloperidone—CYP2D6—hematopoietic system—hematologic cancer	0.000359	0.0195	CbGeAlD
Iloperidone—ADRA2A—gonad—hematologic cancer	0.000352	0.0192	CbGeAlD
Iloperidone—DRD2—lung—hematologic cancer	0.000347	0.0189	CbGeAlD
Iloperidone—HTR7—testis—hematologic cancer	0.000346	0.0189	CbGeAlD
Iloperidone—ADRA2C—lung—hematologic cancer	0.000337	0.0184	CbGeAlD
Iloperidone—CYP1A2—blood—hematologic cancer	0.000334	0.0182	CbGeAlD
Iloperidone—DRD2—testis—hematologic cancer	0.000328	0.0178	CbGeAlD
Iloperidone—CYP3A5—blood—hematologic cancer	0.000322	0.0175	CbGeAlD
Iloperidone—ADRA2C—testis—hematologic cancer	0.000318	0.0173	CbGeAlD
Iloperidone—ADRA2A—blood—hematologic cancer	0.000307	0.0167	CbGeAlD
Iloperidone—CYP2E1—blood—hematologic cancer	0.0003	0.0164	CbGeAlD
Iloperidone—HTR2A—gonad—hematologic cancer	0.0003	0.0163	CbGeAlD
Iloperidone—SIGMAR1—lymph node—hematologic cancer	0.000294	0.016	CbGeAlD
Iloperidone—CYP1A2—lung—hematologic cancer	0.000293	0.0159	CbGeAlD
Iloperidone—CYP3A5—lung—hematologic cancer	0.000282	0.0154	CbGeAlD
Iloperidone—HRH1—lung—hematologic cancer	0.000274	0.0149	CbGeAlD
Iloperidone—ADRA2A—lung—hematologic cancer	0.000269	0.0147	CbGeAlD
Iloperidone—CYP2E1—lung—hematologic cancer	0.000263	0.0143	CbGeAlD
Iloperidone—HTR2A—blood—hematologic cancer	0.000261	0.0142	CbGeAlD
Iloperidone—HRH1—testis—hematologic cancer	0.000259	0.0141	CbGeAlD
Iloperidone—ADRA2A—testis—hematologic cancer	0.000254	0.0138	CbGeAlD
Iloperidone—CYP2E1—testis—hematologic cancer	0.000249	0.0135	CbGeAlD
Iloperidone—Risperidone—ABCB1—hematologic cancer	0.000242	0.0731	CrCbGaD
Iloperidone—CYP3A4—blood—hematologic cancer	0.000242	0.0132	CbGeAlD
Iloperidone—CYP2D6—blood—hematologic cancer	0.000238	0.013	CbGeAlD
Iloperidone—ADRA2C—lymph node—hematologic cancer	0.000231	0.0126	CbGeAlD
Iloperidone—HTR2A—lung—hematologic cancer	0.000229	0.0125	CbGeAlD
Iloperidone—HTR2A—testis—hematologic cancer	0.000216	0.0118	CbGeAlD
Iloperidone—CYP2D6—testis—hematologic cancer	0.000197	0.0107	CbGeAlD
Iloperidone—HRH1—lymph node—hematologic cancer	0.000187	0.0102	CbGeAlD
Iloperidone—ADRA2A—lymph node—hematologic cancer	0.000184	0.01	CbGeAlD
Iloperidone—Gefitinib—ALB—hematologic cancer	0.000171	0.0517	CrCbGaD
Iloperidone—Gefitinib—ABCB1—hematologic cancer	0.000164	0.0494	CrCbGaD
Iloperidone—Fatigue—Etoposide—hematologic cancer	4.69e-05	0.000172	CcSEcCtD
Iloperidone—Myalgia—Dexamethasone—hematologic cancer	4.67e-05	0.000172	CcSEcCtD
Iloperidone—Myalgia—Betamethasone—hematologic cancer	4.67e-05	0.000172	CcSEcCtD
Iloperidone—Stomatitis—Epirubicin—hematologic cancer	4.66e-05	0.000171	CcSEcCtD
Iloperidone—Dizziness—Carmustine—hematologic cancer	4.65e-05	0.000171	CcSEcCtD
Iloperidone—Conjunctivitis—Epirubicin—hematologic cancer	4.65e-05	0.000171	CcSEcCtD
Iloperidone—Dysuria—Doxorubicin—hematologic cancer	4.64e-05	0.00017	CcSEcCtD
Iloperidone—Rash—Thalidomide—hematologic cancer	4.62e-05	0.00017	CcSEcCtD
Iloperidone—Dermatitis—Thalidomide—hematologic cancer	4.62e-05	0.00017	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Doxorubicin—hematologic cancer	4.61e-05	0.000169	CcSEcCtD
Iloperidone—Dizziness—Alitretinoin—hematologic cancer	4.61e-05	0.000169	CcSEcCtD
Iloperidone—Diarrhoea—Vincristine—hematologic cancer	4.6e-05	0.000169	CcSEcCtD
Iloperidone—Pollakiuria—Doxorubicin—hematologic cancer	4.59e-05	0.000168	CcSEcCtD
Iloperidone—Asthenia—Gemcitabine—hematologic cancer	4.57e-05	0.000168	CcSEcCtD
Iloperidone—Dizziness—Ifosfamide—hematologic cancer	4.56e-05	0.000167	CcSEcCtD
Iloperidone—Urinary tract disorder—Methotrexate—hematologic cancer	4.53e-05	0.000166	CcSEcCtD
Iloperidone—Hepatobiliary disease—Epirubicin—hematologic cancer	4.52e-05	0.000166	CcSEcCtD
Iloperidone—Weight increased—Doxorubicin—hematologic cancer	4.52e-05	0.000166	CcSEcCtD
Iloperidone—Epistaxis—Epirubicin—hematologic cancer	4.51e-05	0.000166	CcSEcCtD
Iloperidone—Vision blurred—Prednisone—hematologic cancer	4.51e-05	0.000165	CcSEcCtD
Iloperidone—Nausea—Thiotepa—hematologic cancer	4.5e-05	0.000165	CcSEcCtD
Iloperidone—Urethral disorder—Methotrexate—hematologic cancer	4.5e-05	0.000165	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	4.5e-05	0.000165	CcSEcCtD
Iloperidone—Weight decreased—Doxorubicin—hematologic cancer	4.49e-05	0.000165	CcSEcCtD
Iloperidone—Feeling abnormal—Etoposide—hematologic cancer	4.49e-05	0.000165	CcSEcCtD
Iloperidone—Oedema—Dexamethasone—hematologic cancer	4.48e-05	0.000165	CcSEcCtD
Iloperidone—Oedema—Betamethasone—hematologic cancer	4.48e-05	0.000165	CcSEcCtD
Iloperidone—Diarrhoea—Irinotecan—hematologic cancer	4.48e-05	0.000164	CcSEcCtD
Iloperidone—Diarrhoea—Mitoxantrone—hematologic cancer	4.48e-05	0.000164	CcSEcCtD
Iloperidone—Infection—Dexamethasone—hematologic cancer	4.45e-05	0.000163	CcSEcCtD
Iloperidone—Infection—Betamethasone—hematologic cancer	4.45e-05	0.000163	CcSEcCtD
Iloperidone—Dizziness—Vincristine—hematologic cancer	4.44e-05	0.000163	CcSEcCtD
Iloperidone—Rash—Carmustine—hematologic cancer	4.44e-05	0.000163	CcSEcCtD
Iloperidone—Dermatitis—Carmustine—hematologic cancer	4.43e-05	0.000163	CcSEcCtD
Iloperidone—Paraesthesia—Triamcinolone—hematologic cancer	4.43e-05	0.000163	CcSEcCtD
Iloperidone—Feeling abnormal—Prednisolone—hematologic cancer	4.42e-05	0.000162	CcSEcCtD
Iloperidone—Anaemia—Prednisone—hematologic cancer	4.42e-05	0.000162	CcSEcCtD
Iloperidone—Dyspnoea—Triamcinolone—hematologic cancer	4.4e-05	0.000162	CcSEcCtD
Iloperidone—Rash—Alitretinoin—hematologic cancer	4.4e-05	0.000161	CcSEcCtD
Iloperidone—Nervous system disorder—Dexamethasone—hematologic cancer	4.39e-05	0.000161	CcSEcCtD
Iloperidone—Nervous system disorder—Betamethasone—hematologic cancer	4.39e-05	0.000161	CcSEcCtD
Iloperidone—Agitation—Prednisone—hematologic cancer	4.39e-05	0.000161	CcSEcCtD
Iloperidone—Dermatitis—Alitretinoin—hematologic cancer	4.39e-05	0.000161	CcSEcCtD
Iloperidone—Tachycardia—Betamethasone—hematologic cancer	4.37e-05	0.000161	CcSEcCtD
Iloperidone—Tachycardia—Dexamethasone—hematologic cancer	4.37e-05	0.000161	CcSEcCtD
Iloperidone—Diarrhoea—Gemcitabine—hematologic cancer	4.36e-05	0.00016	CcSEcCtD
Iloperidone—Nausea—Thalidomide—hematologic cancer	4.35e-05	0.00016	CcSEcCtD
Iloperidone—Rash—Ifosfamide—hematologic cancer	4.35e-05	0.00016	CcSEcCtD
Iloperidone—Dermatitis—Ifosfamide—hematologic cancer	4.34e-05	0.000159	CcSEcCtD
Iloperidone—Dizziness—Irinotecan—hematologic cancer	4.33e-05	0.000159	CcSEcCtD
Iloperidone—Stomatitis—Doxorubicin—hematologic cancer	4.32e-05	0.000158	CcSEcCtD
Iloperidone—Body temperature increased—Etoposide—hematologic cancer	4.3e-05	0.000158	CcSEcCtD
Iloperidone—Conjunctivitis—Doxorubicin—hematologic cancer	4.3e-05	0.000158	CcSEcCtD
Iloperidone—Vertigo—Prednisone—hematologic cancer	4.29e-05	0.000158	CcSEcCtD
Iloperidone—Eye disorder—Methotrexate—hematologic cancer	4.29e-05	0.000157	CcSEcCtD
Iloperidone—Tinnitus—Methotrexate—hematologic cancer	4.28e-05	0.000157	CcSEcCtD
Iloperidone—Asthenia—Cisplatin—hematologic cancer	4.26e-05	0.000157	CcSEcCtD
Iloperidone—Cardiac disorder—Methotrexate—hematologic cancer	4.26e-05	0.000156	CcSEcCtD
Iloperidone—Fatigue—Triamcinolone—hematologic cancer	4.26e-05	0.000156	CcSEcCtD
Iloperidone—Urinary tract disorder—Epirubicin—hematologic cancer	4.24e-05	0.000156	CcSEcCtD
Iloperidone—Rash—Vincristine—hematologic cancer	4.24e-05	0.000156	CcSEcCtD
Iloperidone—Dermatitis—Vincristine—hematologic cancer	4.23e-05	0.000155	CcSEcCtD
Iloperidone—Connective tissue disorder—Epirubicin—hematologic cancer	4.22e-05	0.000155	CcSEcCtD
Iloperidone—Urethral disorder—Epirubicin—hematologic cancer	4.21e-05	0.000155	CcSEcCtD
Iloperidone—Hepatobiliary disease—Doxorubicin—hematologic cancer	4.19e-05	0.000154	CcSEcCtD
Iloperidone—Hypotension—Dexamethasone—hematologic cancer	4.19e-05	0.000154	CcSEcCtD
Iloperidone—Hypotension—Betamethasone—hematologic cancer	4.19e-05	0.000154	CcSEcCtD
Iloperidone—Nausea—Carmustine—hematologic cancer	4.18e-05	0.000154	CcSEcCtD
Iloperidone—Epistaxis—Doxorubicin—hematologic cancer	4.18e-05	0.000153	CcSEcCtD
Iloperidone—Angiopathy—Methotrexate—hematologic cancer	4.16e-05	0.000153	CcSEcCtD
Iloperidone—Nausea—Alitretinoin—hematologic cancer	4.14e-05	0.000152	CcSEcCtD
Iloperidone—Mediastinal disorder—Methotrexate—hematologic cancer	4.14e-05	0.000152	CcSEcCtD
Iloperidone—Rash—Mitoxantrone—hematologic cancer	4.13e-05	0.000152	CcSEcCtD
Iloperidone—Rash—Irinotecan—hematologic cancer	4.13e-05	0.000152	CcSEcCtD
Iloperidone—Dermatitis—Irinotecan—hematologic cancer	4.12e-05	0.000151	CcSEcCtD
Iloperidone—Dermatitis—Mitoxantrone—hematologic cancer	4.12e-05	0.000151	CcSEcCtD
Iloperidone—Nausea—Ifosfamide—hematologic cancer	4.09e-05	0.00015	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	4.08e-05	0.00015	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Betamethasone—hematologic cancer	4.08e-05	0.00015	CcSEcCtD
Iloperidone—Arthralgia—Prednisone—hematologic cancer	4.07e-05	0.000149	CcSEcCtD
Iloperidone—Myalgia—Prednisone—hematologic cancer	4.07e-05	0.000149	CcSEcCtD
Iloperidone—Feeling abnormal—Triamcinolone—hematologic cancer	4.07e-05	0.000149	CcSEcCtD
Iloperidone—Diarrhoea—Cisplatin—hematologic cancer	4.07e-05	0.000149	CcSEcCtD
Iloperidone—Paraesthesia—Dexamethasone—hematologic cancer	4.02e-05	0.000148	CcSEcCtD
Iloperidone—Paraesthesia—Betamethasone—hematologic cancer	4.02e-05	0.000148	CcSEcCtD
Iloperidone—Mental disorder—Methotrexate—hematologic cancer	4.02e-05	0.000148	CcSEcCtD
Iloperidone—Rash—Gemcitabine—hematologic cancer	4.02e-05	0.000148	CcSEcCtD
Iloperidone—Dermatitis—Gemcitabine—hematologic cancer	4.02e-05	0.000147	CcSEcCtD
Iloperidone—Eye disorder—Epirubicin—hematologic cancer	4.01e-05	0.000147	CcSEcCtD
Iloperidone—Tinnitus—Epirubicin—hematologic cancer	4e-05	0.000147	CcSEcCtD
Iloperidone—Malnutrition—Methotrexate—hematologic cancer	4e-05	0.000147	CcSEcCtD
Iloperidone—Nausea—Vincristine—hematologic cancer	3.99e-05	0.000147	CcSEcCtD
Iloperidone—Cardiac disorder—Epirubicin—hematologic cancer	3.99e-05	0.000146	CcSEcCtD
Iloperidone—Urinary tract disorder—Doxorubicin—hematologic cancer	3.92e-05	0.000144	CcSEcCtD
Iloperidone—Asthenia—Etoposide—hematologic cancer	3.91e-05	0.000143	CcSEcCtD
Iloperidone—Connective tissue disorder—Doxorubicin—hematologic cancer	3.91e-05	0.000143	CcSEcCtD
Iloperidone—Body temperature increased—Triamcinolone—hematologic cancer	3.9e-05	0.000143	CcSEcCtD
Iloperidone—Oedema—Prednisone—hematologic cancer	3.9e-05	0.000143	CcSEcCtD
Iloperidone—Angiopathy—Epirubicin—hematologic cancer	3.9e-05	0.000143	CcSEcCtD
Iloperidone—Urethral disorder—Doxorubicin—hematologic cancer	3.9e-05	0.000143	CcSEcCtD
Iloperidone—Nausea—Mitoxantrone—hematologic cancer	3.89e-05	0.000143	CcSEcCtD
Iloperidone—Nausea—Irinotecan—hematologic cancer	3.89e-05	0.000143	CcSEcCtD
Iloperidone—Infection—Prednisone—hematologic cancer	3.88e-05	0.000142	CcSEcCtD
Iloperidone—Mediastinal disorder—Epirubicin—hematologic cancer	3.87e-05	0.000142	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.87e-05	0.000142	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.87e-05	0.000142	CcSEcCtD
Iloperidone—Fatigue—Dexamethasone—hematologic cancer	3.86e-05	0.000142	CcSEcCtD
Iloperidone—Fatigue—Betamethasone—hematologic cancer	3.86e-05	0.000142	CcSEcCtD
Iloperidone—Arrhythmia—Epirubicin—hematologic cancer	3.84e-05	0.000141	CcSEcCtD
Iloperidone—Nervous system disorder—Prednisone—hematologic cancer	3.83e-05	0.00014	CcSEcCtD
Iloperidone—Tachycardia—Prednisone—hematologic cancer	3.81e-05	0.00014	CcSEcCtD
Iloperidone—Nausea—Gemcitabine—hematologic cancer	3.79e-05	0.000139	CcSEcCtD
Iloperidone—Vision blurred—Methotrexate—hematologic cancer	3.77e-05	0.000138	CcSEcCtD
Iloperidone—Mental disorder—Epirubicin—hematologic cancer	3.76e-05	0.000138	CcSEcCtD
Iloperidone—Rash—Cisplatin—hematologic cancer	3.75e-05	0.000138	CcSEcCtD
Iloperidone—Dermatitis—Cisplatin—hematologic cancer	3.74e-05	0.000137	CcSEcCtD
Iloperidone—Malnutrition—Epirubicin—hematologic cancer	3.74e-05	0.000137	CcSEcCtD
Iloperidone—Diarrhoea—Etoposide—hematologic cancer	3.72e-05	0.000137	CcSEcCtD
Iloperidone—Eye disorder—Doxorubicin—hematologic cancer	3.71e-05	0.000136	CcSEcCtD
Iloperidone—Tinnitus—Doxorubicin—hematologic cancer	3.71e-05	0.000136	CcSEcCtD
Iloperidone—Anaemia—Methotrexate—hematologic cancer	3.69e-05	0.000136	CcSEcCtD
Iloperidone—Feeling abnormal—Dexamethasone—hematologic cancer	3.69e-05	0.000136	CcSEcCtD
Iloperidone—Feeling abnormal—Betamethasone—hematologic cancer	3.69e-05	0.000136	CcSEcCtD
Iloperidone—Cardiac disorder—Doxorubicin—hematologic cancer	3.69e-05	0.000135	CcSEcCtD
Iloperidone—Angiopathy—Doxorubicin—hematologic cancer	3.61e-05	0.000132	CcSEcCtD
Iloperidone—Dizziness—Etoposide—hematologic cancer	3.6e-05	0.000132	CcSEcCtD
Iloperidone—Muscle spasms—Epirubicin—hematologic cancer	3.59e-05	0.000132	CcSEcCtD
Iloperidone—Vertigo—Methotrexate—hematologic cancer	3.59e-05	0.000132	CcSEcCtD
Iloperidone—Mediastinal disorder—Doxorubicin—hematologic cancer	3.58e-05	0.000132	CcSEcCtD
Iloperidone—Leukopenia—Methotrexate—hematologic cancer	3.58e-05	0.000131	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.55e-05	0.000131	CcSEcCtD
Iloperidone—Dizziness—Prednisolone—hematologic cancer	3.55e-05	0.00013	CcSEcCtD
Iloperidone—Arrhythmia—Doxorubicin—hematologic cancer	3.55e-05	0.00013	CcSEcCtD
Iloperidone—Asthenia—Triamcinolone—hematologic cancer	3.54e-05	0.00013	CcSEcCtD
Iloperidone—Body temperature increased—Dexamethasone—hematologic cancer	3.54e-05	0.00013	CcSEcCtD
Iloperidone—Body temperature increased—Betamethasone—hematologic cancer	3.54e-05	0.00013	CcSEcCtD
Iloperidone—Nausea—Cisplatin—hematologic cancer	3.53e-05	0.00013	CcSEcCtD
Iloperidone—Vision blurred—Epirubicin—hematologic cancer	3.52e-05	0.000129	CcSEcCtD
Iloperidone—Paraesthesia—Prednisone—hematologic cancer	3.5e-05	0.000129	CcSEcCtD
Iloperidone—Mental disorder—Doxorubicin—hematologic cancer	3.48e-05	0.000128	CcSEcCtD
Iloperidone—Malnutrition—Doxorubicin—hematologic cancer	3.46e-05	0.000127	CcSEcCtD
Iloperidone—Anaemia—Epirubicin—hematologic cancer	3.46e-05	0.000127	CcSEcCtD
Iloperidone—Agitation—Epirubicin—hematologic cancer	3.44e-05	0.000126	CcSEcCtD
Iloperidone—Rash—Etoposide—hematologic cancer	3.43e-05	0.000126	CcSEcCtD
Iloperidone—Dermatitis—Etoposide—hematologic cancer	3.43e-05	0.000126	CcSEcCtD
Iloperidone—Arthralgia—Methotrexate—hematologic cancer	3.4e-05	0.000125	CcSEcCtD
Iloperidone—Myalgia—Methotrexate—hematologic cancer	3.4e-05	0.000125	CcSEcCtD
Iloperidone—Rash—Prednisolone—hematologic cancer	3.39e-05	0.000124	CcSEcCtD
Iloperidone—Dermatitis—Prednisolone—hematologic cancer	3.38e-05	0.000124	CcSEcCtD
Iloperidone—Fatigue—Prednisone—hematologic cancer	3.36e-05	0.000124	CcSEcCtD
Iloperidone—Vertigo—Epirubicin—hematologic cancer	3.36e-05	0.000123	CcSEcCtD
Iloperidone—Leukopenia—Epirubicin—hematologic cancer	3.35e-05	0.000123	CcSEcCtD
Iloperidone—Muscle spasms—Doxorubicin—hematologic cancer	3.33e-05	0.000122	CcSEcCtD
Iloperidone—Palpitations—Epirubicin—hematologic cancer	3.3e-05	0.000121	CcSEcCtD
Iloperidone—Confusional state—Methotrexate—hematologic cancer	3.29e-05	0.000121	CcSEcCtD
Iloperidone—Dizziness—Triamcinolone—hematologic cancer	3.26e-05	0.00012	CcSEcCtD
Iloperidone—Vision blurred—Doxorubicin—hematologic cancer	3.26e-05	0.00012	CcSEcCtD
Iloperidone—Infection—Methotrexate—hematologic cancer	3.24e-05	0.000119	CcSEcCtD
Iloperidone—Nausea—Etoposide—hematologic cancer	3.23e-05	0.000119	CcSEcCtD
Iloperidone—Feeling abnormal—Prednisone—hematologic cancer	3.22e-05	0.000118	CcSEcCtD
Iloperidone—Asthenia—Betamethasone—hematologic cancer	3.21e-05	0.000118	CcSEcCtD
Iloperidone—Asthenia—Dexamethasone—hematologic cancer	3.21e-05	0.000118	CcSEcCtD
Iloperidone—Nervous system disorder—Methotrexate—hematologic cancer	3.2e-05	0.000117	CcSEcCtD
Iloperidone—Anaemia—Doxorubicin—hematologic cancer	3.2e-05	0.000117	CcSEcCtD
Iloperidone—Nausea—Prednisolone—hematologic cancer	3.19e-05	0.000117	CcSEcCtD
Iloperidone—Arthralgia—Epirubicin—hematologic cancer	3.18e-05	0.000117	CcSEcCtD
Iloperidone—Myalgia—Epirubicin—hematologic cancer	3.18e-05	0.000117	CcSEcCtD
Iloperidone—Agitation—Doxorubicin—hematologic cancer	3.18e-05	0.000117	CcSEcCtD
Iloperidone—Rash—Triamcinolone—hematologic cancer	3.11e-05	0.000114	CcSEcCtD
Iloperidone—Dry mouth—Epirubicin—hematologic cancer	3.11e-05	0.000114	CcSEcCtD
Iloperidone—Dermatitis—Triamcinolone—hematologic cancer	3.11e-05	0.000114	CcSEcCtD
Iloperidone—Vertigo—Doxorubicin—hematologic cancer	3.11e-05	0.000114	CcSEcCtD
Iloperidone—Leukopenia—Doxorubicin—hematologic cancer	3.1e-05	0.000114	CcSEcCtD
Iloperidone—Body temperature increased—Prednisone—hematologic cancer	3.08e-05	0.000113	CcSEcCtD
Iloperidone—Confusional state—Epirubicin—hematologic cancer	3.08e-05	0.000113	CcSEcCtD
Iloperidone—Diarrhoea—Betamethasone—hematologic cancer	3.07e-05	0.000113	CcSEcCtD
Iloperidone—Diarrhoea—Dexamethasone—hematologic cancer	3.07e-05	0.000113	CcSEcCtD
Iloperidone—Palpitations—Doxorubicin—hematologic cancer	3.06e-05	0.000112	CcSEcCtD
Iloperidone—Oedema—Epirubicin—hematologic cancer	3.05e-05	0.000112	CcSEcCtD
Iloperidone—Hypotension—Methotrexate—hematologic cancer	3.05e-05	0.000112	CcSEcCtD
Iloperidone—Infection—Epirubicin—hematologic cancer	3.03e-05	0.000111	CcSEcCtD
Iloperidone—Nervous system disorder—Epirubicin—hematologic cancer	2.99e-05	0.00011	CcSEcCtD
Iloperidone—Tachycardia—Epirubicin—hematologic cancer	2.98e-05	0.000109	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.97e-05	0.000109	CcSEcCtD
Iloperidone—Dizziness—Betamethasone—hematologic cancer	2.96e-05	0.000109	CcSEcCtD
Iloperidone—Dizziness—Dexamethasone—hematologic cancer	2.96e-05	0.000109	CcSEcCtD
Iloperidone—Arthralgia—Doxorubicin—hematologic cancer	2.95e-05	0.000108	CcSEcCtD
Iloperidone—Myalgia—Doxorubicin—hematologic cancer	2.95e-05	0.000108	CcSEcCtD
Iloperidone—Nausea—Triamcinolone—hematologic cancer	2.93e-05	0.000108	CcSEcCtD
Iloperidone—Paraesthesia—Methotrexate—hematologic cancer	2.93e-05	0.000108	CcSEcCtD
Iloperidone—Dyspnoea—Methotrexate—hematologic cancer	2.91e-05	0.000107	CcSEcCtD
Iloperidone—Somnolence—Methotrexate—hematologic cancer	2.9e-05	0.000106	CcSEcCtD
Iloperidone—Dry mouth—Doxorubicin—hematologic cancer	2.88e-05	0.000106	CcSEcCtD
Iloperidone—Hypotension—Epirubicin—hematologic cancer	2.85e-05	0.000105	CcSEcCtD
Iloperidone—Confusional state—Doxorubicin—hematologic cancer	2.85e-05	0.000105	CcSEcCtD
Iloperidone—Rash—Betamethasone—hematologic cancer	2.82e-05	0.000104	CcSEcCtD
Iloperidone—Rash—Dexamethasone—hematologic cancer	2.82e-05	0.000104	CcSEcCtD
Iloperidone—Oedema—Doxorubicin—hematologic cancer	2.82e-05	0.000104	CcSEcCtD
Iloperidone—Dermatitis—Betamethasone—hematologic cancer	2.82e-05	0.000104	CcSEcCtD
Iloperidone—Dermatitis—Dexamethasone—hematologic cancer	2.82e-05	0.000104	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.81e-05	0.000103	CcSEcCtD
Iloperidone—Fatigue—Methotrexate—hematologic cancer	2.81e-05	0.000103	CcSEcCtD
Iloperidone—Infection—Doxorubicin—hematologic cancer	2.8e-05	0.000103	CcSEcCtD
Iloperidone—Asthenia—Prednisone—hematologic cancer	2.8e-05	0.000103	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.78e-05	0.000102	CcSEcCtD
Iloperidone—Nervous system disorder—Doxorubicin—hematologic cancer	2.77e-05	0.000102	CcSEcCtD
Iloperidone—Tachycardia—Doxorubicin—hematologic cancer	2.76e-05	0.000101	CcSEcCtD
Iloperidone—Paraesthesia—Epirubicin—hematologic cancer	2.74e-05	0.000101	CcSEcCtD
Iloperidone—Dyspnoea—Epirubicin—hematologic cancer	2.72e-05	9.99e-05	CcSEcCtD
Iloperidone—Somnolence—Epirubicin—hematologic cancer	2.71e-05	9.96e-05	CcSEcCtD
Iloperidone—Feeling abnormal—Methotrexate—hematologic cancer	2.69e-05	9.87e-05	CcSEcCtD
Iloperidone—Diarrhoea—Prednisone—hematologic cancer	2.67e-05	9.8e-05	CcSEcCtD
Iloperidone—Nausea—Dexamethasone—hematologic cancer	2.66e-05	9.77e-05	CcSEcCtD
Iloperidone—Nausea—Betamethasone—hematologic cancer	2.66e-05	9.77e-05	CcSEcCtD
Iloperidone—Hypotension—Doxorubicin—hematologic cancer	2.64e-05	9.69e-05	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.63e-05	9.67e-05	CcSEcCtD
Iloperidone—Fatigue—Epirubicin—hematologic cancer	2.63e-05	9.66e-05	CcSEcCtD
Iloperidone—Dizziness—Prednisone—hematologic cancer	2.58e-05	9.47e-05	CcSEcCtD
Iloperidone—Body temperature increased—Methotrexate—hematologic cancer	2.58e-05	9.46e-05	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.57e-05	9.45e-05	CcSEcCtD
Iloperidone—Paraesthesia—Doxorubicin—hematologic cancer	2.54e-05	9.31e-05	CcSEcCtD
Iloperidone—Dyspnoea—Doxorubicin—hematologic cancer	2.52e-05	9.24e-05	CcSEcCtD
Iloperidone—Feeling abnormal—Epirubicin—hematologic cancer	2.51e-05	9.23e-05	CcSEcCtD
Iloperidone—Somnolence—Doxorubicin—hematologic cancer	2.51e-05	9.22e-05	CcSEcCtD
Iloperidone—Rash—Prednisone—hematologic cancer	2.46e-05	9.03e-05	CcSEcCtD
Iloperidone—Dermatitis—Prednisone—hematologic cancer	2.46e-05	9.02e-05	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.44e-05	8.95e-05	CcSEcCtD
Iloperidone—Fatigue—Doxorubicin—hematologic cancer	2.43e-05	8.94e-05	CcSEcCtD
Iloperidone—Body temperature increased—Epirubicin—hematologic cancer	2.41e-05	8.86e-05	CcSEcCtD
Iloperidone—Asthenia—Methotrexate—hematologic cancer	2.34e-05	8.59e-05	CcSEcCtD
Iloperidone—Feeling abnormal—Doxorubicin—hematologic cancer	2.33e-05	8.54e-05	CcSEcCtD
Iloperidone—Nausea—Prednisone—hematologic cancer	2.32e-05	8.51e-05	CcSEcCtD
Iloperidone—Body temperature increased—Doxorubicin—hematologic cancer	2.23e-05	8.2e-05	CcSEcCtD
Iloperidone—Diarrhoea—Methotrexate—hematologic cancer	2.23e-05	8.19e-05	CcSEcCtD
Iloperidone—Asthenia—Epirubicin—hematologic cancer	2.19e-05	8.04e-05	CcSEcCtD
Iloperidone—Dizziness—Methotrexate—hematologic cancer	2.16e-05	7.92e-05	CcSEcCtD
Iloperidone—Diarrhoea—Epirubicin—hematologic cancer	2.09e-05	7.67e-05	CcSEcCtD
Iloperidone—Rash—Methotrexate—hematologic cancer	2.06e-05	7.55e-05	CcSEcCtD
Iloperidone—Dermatitis—Methotrexate—hematologic cancer	2.05e-05	7.54e-05	CcSEcCtD
Iloperidone—Asthenia—Doxorubicin—hematologic cancer	2.03e-05	7.44e-05	CcSEcCtD
Iloperidone—Dizziness—Epirubicin—hematologic cancer	2.02e-05	7.41e-05	CcSEcCtD
Iloperidone—Nausea—Methotrexate—hematologic cancer	1.94e-05	7.11e-05	CcSEcCtD
Iloperidone—Diarrhoea—Doxorubicin—hematologic cancer	1.93e-05	7.09e-05	CcSEcCtD
Iloperidone—Rash—Epirubicin—hematologic cancer	1.92e-05	7.06e-05	CcSEcCtD
Iloperidone—Dermatitis—Epirubicin—hematologic cancer	1.92e-05	7.06e-05	CcSEcCtD
Iloperidone—Dizziness—Doxorubicin—hematologic cancer	1.87e-05	6.86e-05	CcSEcCtD
Iloperidone—Nausea—Epirubicin—hematologic cancer	1.81e-05	6.66e-05	CcSEcCtD
Iloperidone—Rash—Doxorubicin—hematologic cancer	1.78e-05	6.54e-05	CcSEcCtD
Iloperidone—Dermatitis—Doxorubicin—hematologic cancer	1.78e-05	6.53e-05	CcSEcCtD
Iloperidone—Nausea—Doxorubicin—hematologic cancer	1.68e-05	6.16e-05	CcSEcCtD
Iloperidone—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	2.22e-06	2.21e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	2.22e-06	2.21e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CDKN1B—hematologic cancer	2.21e-06	2.21e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	2.21e-06	2.21e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	2.21e-06	2.21e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CASP3—hematologic cancer	2.21e-06	2.2e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IL2—hematologic cancer	2.2e-06	2.2e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—MTHFR—hematologic cancer	2.2e-06	2.2e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—IL6—hematologic cancer	2.19e-06	2.19e-05	CbGpPWpGaD
Iloperidone—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	2.19e-06	2.19e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—SRC—hematologic cancer	2.19e-06	2.19e-05	CbGpPWpGaD
Iloperidone—HRH1—GPCR downstream signaling—AKT1—hematologic cancer	2.19e-06	2.18e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.19e-06	2.18e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—EP300—hematologic cancer	2.18e-06	2.18e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—SRC—hematologic cancer	2.18e-06	2.18e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TP53—hematologic cancer	2.18e-06	2.18e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TP53—hematologic cancer	2.18e-06	2.17e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CASP3—hematologic cancer	2.17e-06	2.17e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	2.17e-06	2.17e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IL2—hematologic cancer	2.17e-06	2.17e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CASP3—hematologic cancer	2.17e-06	2.16e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IL2—hematologic cancer	2.16e-06	2.16e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TP53—hematologic cancer	2.16e-06	2.16e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—IL6—hematologic cancer	2.16e-06	2.16e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—IL6—hematologic cancer	2.15e-06	2.15e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—PIK3CA—hematologic cancer	2.15e-06	2.15e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CCND1—hematologic cancer	2.15e-06	2.15e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	2.15e-06	2.15e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	2.15e-06	2.15e-05	CbGpPWpGaD
Iloperidone—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	2.15e-06	2.14e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—JUN—hematologic cancer	2.14e-06	2.14e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	2.13e-06	2.13e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	2.13e-06	2.12e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IL2—hematologic cancer	2.12e-06	2.12e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	2.12e-06	2.12e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—SRC—hematologic cancer	2.12e-06	2.12e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—EP300—hematologic cancer	2.12e-06	2.11e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CCND1—hematologic cancer	2.11e-06	2.11e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	2.11e-06	2.11e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—STAT3—hematologic cancer	2.11e-06	2.11e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—JUN—hematologic cancer	2.11e-06	2.11e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CCND1—hematologic cancer	2.11e-06	2.11e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—KRAS—hematologic cancer	2.11e-06	2.11e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—NRAS—hematologic cancer	2.11e-06	2.1e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—JUN—hematologic cancer	2.11e-06	2.1e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—STAT3—hematologic cancer	2.1e-06	2.1e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—NRAS—hematologic cancer	2.1e-06	2.09e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.09e-06	2.09e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—HRAS—hematologic cancer	2.08e-06	2.08e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TP53—hematologic cancer	2.08e-06	2.08e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—KRAS—hematologic cancer	2.08e-06	2.08e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—HRAS—hematologic cancer	2.08e-06	2.08e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	2.08e-06	2.08e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—PTEN—hematologic cancer	2.07e-06	2.07e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	2.07e-06	2.07e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—HRAS—hematologic cancer	2.07e-06	2.06e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—JUN—hematologic cancer	2.07e-06	2.06e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	2.07e-06	2.06e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	2.05e-06	2.05e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	2.05e-06	2.04e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	2.04e-06	2.04e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CDKN1A—hematologic cancer	2.04e-06	2.04e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—PTEN—hematologic cancer	2.04e-06	2.04e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	2.04e-06	2.04e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PTEN—hematologic cancer	2.04e-06	2.04e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—PTEN—hematologic cancer	2.04e-06	2.03e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PTEN—hematologic cancer	2.04e-06	2.03e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MAPK8—hematologic cancer	2.03e-06	2.03e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—CREBBP—hematologic cancer	2.03e-06	2.02e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—AKT1—hematologic cancer	2.02e-06	2.02e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	2.02e-06	2.02e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	2.02e-06	2.01e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	2.01e-06	2.01e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	2e-06	2e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	2e-06	2e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	2e-06	1.99e-05	CbGpPWpGaD
Iloperidone—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	2e-06	1.99e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—IL6—hematologic cancer	1.99e-06	1.99e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MAPK8—hematologic cancer	1.99e-06	1.99e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—HRAS—hematologic cancer	1.99e-06	1.99e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—IL6—hematologic cancer	1.99e-06	1.99e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	1.99e-06	1.99e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—AKT1—hematologic cancer	1.99e-06	1.98e-05	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—PIK3CA—hematologic cancer	1.99e-06	1.98e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.98e-06	1.98e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—IL6—hematologic cancer	1.98e-06	1.98e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—EP300—hematologic cancer	1.98e-06	1.98e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	1.98e-06	1.97e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IL2—hematologic cancer	1.97e-06	1.97e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	1.96e-06	1.96e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MYC—hematologic cancer	1.96e-06	1.96e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	1.96e-06	1.96e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	1.96e-06	1.95e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	1.95e-06	1.95e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MYC—hematologic cancer	1.95e-06	1.95e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	1.95e-06	1.95e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	1.95e-06	1.95e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—EP300—hematologic cancer	1.95e-06	1.94e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—EP300—hematologic cancer	1.94e-06	1.94e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—EP300—hematologic cancer	1.94e-06	1.94e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.94e-06	1.94e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—EP300—hematologic cancer	1.94e-06	1.94e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—PIK3CA—hematologic cancer	1.94e-06	1.94e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—PIK3CA—hematologic cancer	1.93e-06	1.93e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.92e-06	1.92e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.92e-06	1.92e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	1.92e-06	1.92e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—SRC—hematologic cancer	1.92e-06	1.92e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.92e-06	1.92e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—JUN—hematologic cancer	1.92e-06	1.92e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—PIK3CA—hematologic cancer	1.91e-06	1.91e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—IL6—hematologic cancer	1.91e-06	1.9e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—EP300—hematologic cancer	1.91e-06	1.9e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MYC—hematologic cancer	1.9e-06	1.9e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—ALB—hematologic cancer	1.9e-06	1.89e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	1.9e-06	1.89e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—SRC—hematologic cancer	1.89e-06	1.89e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—SRC—hematologic cancer	1.89e-06	1.89e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TP53—hematologic cancer	1.88e-06	1.87e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—VEGFA—hematologic cancer	1.87e-06	1.87e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	1.86e-06	1.86e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	1.86e-06	1.85e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—STAT3—hematologic cancer	1.86e-06	1.85e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—SRC—hematologic cancer	1.85e-06	1.85e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.85e-06	1.85e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—NRAS—hematologic cancer	1.85e-06	1.85e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TP53—hematologic cancer	1.85e-06	1.85e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	1.84e-06	1.84e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—VEGFA—hematologic cancer	1.84e-06	1.84e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—AKT1—hematologic cancer	1.84e-06	1.84e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—AKT1—hematologic cancer	1.84e-06	1.83e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—AKT1—hematologic cancer	1.83e-06	1.82e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—STAT3—hematologic cancer	1.83e-06	1.82e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—STAT3—hematologic cancer	1.82e-06	1.82e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—NRAS—hematologic cancer	1.82e-06	1.82e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—NRAS—hematologic cancer	1.82e-06	1.81e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	1.82e-06	1.81e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.81e-06	1.81e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—KRAS—hematologic cancer	1.81e-06	1.81e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	1.81e-06	1.81e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	1.81e-06	1.8e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—KRAS—hematologic cancer	1.81e-06	1.8e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—HRAS—hematologic cancer	1.79e-06	1.79e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	1.79e-06	1.78e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	1.78e-06	1.78e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MAPK3—hematologic cancer	1.77e-06	1.77e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—EP300—hematologic cancer	1.77e-06	1.77e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—HRAS—hematologic cancer	1.77e-06	1.77e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—AKT1—hematologic cancer	1.76e-06	1.76e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	1.76e-06	1.75e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	1.74e-06	1.74e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MAPK3—hematologic cancer	1.74e-06	1.74e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MYC—hematologic cancer	1.72e-06	1.72e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—SRC—hematologic cancer	1.72e-06	1.72e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TGFB1—hematologic cancer	1.72e-06	1.72e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.72e-06	1.71e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—IL6—hematologic cancer	1.72e-06	1.71e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	1.71e-06	1.71e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.7e-06	1.7e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MYC—hematologic cancer	1.7e-06	1.69e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—IL6—hematologic cancer	1.69e-06	1.69e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MYC—hematologic cancer	1.69e-06	1.69e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	1.69e-06	1.69e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TGFB1—hematologic cancer	1.69e-06	1.69e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	1.68e-06	1.67e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.67e-06	1.67e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	1.67e-06	1.66e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MYC—hematologic cancer	1.66e-06	1.66e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	1.66e-06	1.66e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	1.66e-06	1.66e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	1.66e-06	1.65e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	1.66e-06	1.65e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.63e-06	1.63e-05	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—AKT1—hematologic cancer	1.62e-06	1.62e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	1.61e-06	1.61e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TP53—hematologic cancer	1.61e-06	1.61e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—ALB—hematologic cancer	1.61e-06	1.6e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TP53—hematologic cancer	1.6e-06	1.6e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—KRAS—hematologic cancer	1.59e-06	1.59e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	1.59e-06	1.58e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—AKT1—hematologic cancer	1.58e-06	1.58e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—AKT1—hematologic cancer	1.58e-06	1.57e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—KRAS—hematologic cancer	1.57e-06	1.57e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PIK3CA—hematologic cancer	1.57e-06	1.56e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—KRAS—hematologic cancer	1.56e-06	1.56e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—AKT1—hematologic cancer	1.56e-06	1.56e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TP53—hematologic cancer	1.56e-06	1.56e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MYC—hematologic cancer	1.54e-06	1.54e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—HRAS—hematologic cancer	1.54e-06	1.54e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	1.54e-06	1.54e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.54e-06	1.53e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	1.53e-06	1.53e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—HRAS—hematologic cancer	1.53e-06	1.53e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	1.49e-06	1.49e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—IL6—hematologic cancer	1.48e-06	1.47e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—IL6—hematologic cancer	1.47e-06	1.47e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	1.46e-06	1.46e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PTEN—hematologic cancer	1.45e-06	1.45e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	1.44e-06	1.44e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PIK3CA—hematologic cancer	1.44e-06	1.44e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	1.44e-06	1.43e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PIK3CA—hematologic cancer	1.44e-06	1.43e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.43e-06	1.43e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—IL6—hematologic cancer	1.43e-06	1.43e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	1.43e-06	1.42e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.42e-06	1.42e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TP53—hematologic cancer	1.42e-06	1.41e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	1.41e-06	1.41e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TP53—hematologic cancer	1.39e-06	1.39e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TP53—hematologic cancer	1.39e-06	1.39e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—EP300—hematologic cancer	1.38e-06	1.38e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TP53—hematologic cancer	1.36e-06	1.36e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—AKT1—hematologic cancer	1.36e-06	1.36e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—AKT1—hematologic cancer	1.35e-06	1.35e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—HRAS—hematologic cancer	1.35e-06	1.35e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—HRAS—hematologic cancer	1.33e-06	1.33e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—HRAS—hematologic cancer	1.33e-06	1.33e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.32e-06	1.32e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	1.32e-06	1.32e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	1.31e-06	1.31e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	1.3e-06	1.3e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IL6—hematologic cancer	1.3e-06	1.29e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—AKT1—hematologic cancer	1.28e-06	1.28e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IL6—hematologic cancer	1.28e-06	1.27e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IL6—hematologic cancer	1.27e-06	1.27e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TP53—hematologic cancer	1.27e-06	1.27e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.26e-06	1.25e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IL6—hematologic cancer	1.25e-06	1.25e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—ALB—hematologic cancer	1.24e-06	1.24e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PTEN—hematologic cancer	1.23e-06	1.22e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	1.21e-06	1.21e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—AKT1—hematologic cancer	1.2e-06	1.19e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.19e-06	1.18e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—AKT1—hematologic cancer	1.18e-06	1.17e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—AKT1—hematologic cancer	1.18e-06	1.17e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—AKT1—hematologic cancer	1.17e-06	1.17e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—AKT1—hematologic cancer	1.17e-06	1.17e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—EP300—hematologic cancer	1.17e-06	1.17e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IL6—hematologic cancer	1.16e-06	1.16e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	1.15e-06	1.15e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.1e-06	1.09e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	1.07e-06	1.07e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.02e-06	1.02e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTEN—hematologic cancer	9.46e-07	9.45e-06	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—EP300—hematologic cancer	9.02e-07	9.01e-06	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CA—hematologic cancer	8.65e-07	8.64e-06	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—AKT1—hematologic cancer	8.34e-07	8.33e-06	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—AKT1—hematologic cancer	7.07e-07	7.06e-06	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CA—hematologic cancer	6.68e-07	6.67e-06	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—AKT1—hematologic cancer	5.45e-07	5.44e-06	CbGpPWpGaD
